Cryo-Hit Cryosurgery System Overview Cryo-Hit Cryosurgery System is a medical device for minimally invasive ultra-low temperature cryoablation of tumors. The Cryo-Hit Cryosurgery System is a product manufactured by Galileo, an Israeli company. Cryo-Hit™ Cryosurgery System Overview The Cryo-Hit™ Cryosurgery System is a medical device for minimally invasive ultra-low temperature cryoablation of tumors. It is the result of the application of aerospace guidance technology, the cold isolation technology of argon gas, to the medical field. The Cryo-Hit™ Cryosurgery System is a product manufactured by Galileo, Israel. Galileo is the world market leader in cryosurgery equipment, research and development headquarters in YOKNEAM, Israel, Galileo Cryo-Hit™ brand is the number one brand in Europe and the United States, the product is currently more than 400 units worldwide, with 33 patented technology. The Cryo-Hit™ Cryosurgery System was approved by the Ministry of Health, the Health Technology and Structures Authority, and the Ministry of Medical Devices in 1997; CE registration in 1999; and FDA registration in 2000. It is the only device in the world approved by FDA for cryoablation treatment of benign and malignant tumors in multiple systems, such as liver, lung, *, uterus, kidney, prostate, nerve (including nerve pain relief) and bone. Cryo-Hit™ Cryosurgery System SFDA registration name “Cryo-Hi Cryosurgery System”, registration number for the State Food and Drug Administration Machinery (into) word 2010 No. 3582774. Cryo-Hit™ cryosurgery system refrigeration principle is the Joule-Thomson principle, that is, the gas throttling effect. Generally within tens of seconds argon gas can rapidly reduce the tip temperature to -175 °C, and helium gas raises the temperature to 45 °C above zero. The cryotherapy principle of Cryo-Hit™ Cryosurgery System is mainly the rapid formation of ice crystals inside and outside the cells after cooling down, which leads to dehydration and rupture of tumor cells. At the same time, freezing causes microvascular constriction, blood flow slows down, micro thrombus formation and blocks blood flow, leading to ischemic necrosis of tumor tissues. After repeated freezing and thawing of tumor cells, cell rupture and cell membrane lysis induce the release of intracellular and in-obscure antigens, stimulate the body to produce antibodies and improve immunity. The Cryo-Hit™ Cryosurgery System consists of three components, namely, a cold-to-heat conversion system, a temperature monitoring system, and a cryoprobe. The cryoprobe is a hollow, airtight puncture needle with a diameter of only 1.47 mm. Inside the probe is a gas line, a throttling nozzle, an expansion space, etc. The gas line inside the needle can withstand the pressure of three oxygen cylinders (6000 psi) and is made of a high-tech alloy. The 1.47mm cryoprobe is available in a variety of models, the common model can form a 4×6cm size ice ball, below -40 degrees Celsius effective treatment range of 1.5×3.5cm size. Smaller tumors can be treated with a single needle, while larger tumors can be treated with multiple needles in the right shape. The temperature sensor is included in the probe above 2mm to monitor the temperature in the center of the frozen area. 1.47mm probe does not have a temperature sensor, so if you need to monitor the temperature, you can insert a separate temperature probe to monitor the temperature in the tissue. The monitored temperature change and freezing time can be displayed on the LCD as a temperature and time curve, so that the operator can understand the freezing process in time. The treatment is usually performed under the guidance of B-ultrasound, CT and MRI, and the whole process of puncture is monitored in real time. Surgical methods include percutaneous puncture, surgical puncture under direct vision, and lumpectomy. During treatment, the probe is inserted into the tumor, the argon gas is turned on, the tumor is frozen for 10 minutes, there is a 3-minute pause, the helium gas is turned on, the temperature is increased for 1 minute, and the procedure is repeated once more, usually taking 25 minutes. For small tumors in early stages, cryotherapy can be used as an alternative to surgery. In advanced, larger tumors, cryotherapy can be used as a palliative treatment to enhance the effectiveness of a combination of treatments that can reduce tumor load, alleviate symptoms, improve quality of life and extend survival time. Cryo-Hit™ Cryosurgery System has a wide range of indications for tumor treatment, mainly applied to various solid tumors throughout the body. It includes liver cancer, lung cancer, prostate cancer, kidney cancer, pancreatic cancer, benign and malignant tumors of bone, adrenal cancer, meningioma, glioma, uterine fibroid, uterine cancer, ovarian cancer, breast cancer, breast fibroid, as well as for cancer pain relief, etc. Currently, the most commonly used are liver cancer and lung cancer. Cryo-Hit™ Cryosurgery System can be used to treat advanced cancers that have lost the opportunity for surgery; patients of advanced age, poor organ function and poor general condition that can hardly tolerate surgery and anesthesia; tumors that occur in multiple centers and are difficult to be completely resected; mid to late stage tumors that have poor radiotherapy results; tumors that have recurred after surgery, radiotherapy and chemotherapy; tumors that have a large load and involve large blood vessels and vital organs; tumors with heavy The tumors with heavy local symptoms, etc. Cryo-Hit™ Cryosurgery System has the advantages of precise positioning, accurate ablation, less trauma, less pain, precise efficacy and wide indications. Compared with traditional surgery, it greatly reduces the surgical risk and complication rate; compared with microwave and radiofrequency minimally invasive treatment means, it can monitor the treatment process and treatment effect without the limitation of anesthesia conditions; compared with radiotherapy and chemotherapy, it does not have the problem that tumor tissues are not sensitive to chemotherapy drugs or limited by the maximum dose of radiotherapy. The disadvantages of cryosurgery are that the tumor cells may remain at the edge of the frozen area and become a source of recurrence, and that excessive freezing can cause serious complications such as organ dehiscence and “cold shock”. The Cryo-Hit™ Cryosurgery System has six advantages over similar products, namely the only MRI-guided cryosurgical intervention, ultra-fine 1.47mm probes, 5 groups of 25 probes, iThaw warming technology without helium warming, multi-point stereo temperature monitoring, and a treatment planning system. The MRI-compatible cryosurgery system represents the highest level of technology in this category and is highly innovative and advanced. As a very mature tumor cryosurgery device, the Cryo-HIT™ Cryosurgery System is the ideal choice for clinical tumor treatment.